The More Life Company (TMLCF) signed a letter of intent with a U.S. compounding pharmacy to advance Quicksome-enabled prescription compounded pharmaceutical products. The proposed relationship would combine its formulation and delivery technology with the partner’s compounding, dispensing, national fulfillment and telemedicine capabilities. It contemplates technology licensing and potential exclusivity within a defined U.S. prescription-compounding field.
Initial applications under evaluation include hormone replacement, peptides and other active compounds. The parties plan to advance equipment and facility requirements, operational readiness, product prioritization and commercial discussions. The LOI is non-binding except for certain customary provisions; due diligence and definitive documentation remain ahead. The partner’s identity is not being disclosed by mutual agreement.
The More Life Company (TMLCF) reported results from an exploratory eight-participant human pharmacokinetic study of USP testosterone formulated with its patented Quicksome™ sublingual delivery technology.
The study used single 5 mg and 15 mg Quicksome tablets in adult males aged 28–71. Rapid systemic appearance of testosterone was observed, with peak serum concentrations generally occurring about 10–30 minutes after dosing and six of eight participants peaking at approximately 20 minutes. For the 15 mg cohort, average pre-dose levels ranged from about 311–432 ng/dL and observed peaks from 1,436–5,981 ng/dL. The two 5 mg participants also showed clear systemic exposure, with peaks of 5,263 ng/dL and 3,616 ng/dL from pre-dose levels of about 626 ng/dL and 272 ng/dL. Serum levels declined progressively, returning toward baseline within several hours, giving the company human pharmacokinetic data to guide dose loading, dissolution optimization and broader hormone platform development.
The More Life Company (TMLCF) reported positive independent field-trial results for its licensed Agrarius plant signaling technology in Brazilian potato crops. In a randomized trial on Orquestra table potatoes, post-emergence Agrarius programs delivered numerical yield gains versus control, with special-grade yield increases of up to 32.5% and total yield increases of up to 27.6%.
A single Agrarius application at 25 days after emergence produced 30.4 tonnes/ha of special-grade potatoes versus 24.6 tonnes/ha for control, and the highest total yield at 41.1 vs 32.2 tonnes/ha. A two-application program at 25 and 45 days after emergence delivered the highest special-grade yield at 32.6 vs 24.6 tonnes/ha, with special-grade potatoes representing about 80.7% of total yield versus 76.4% in control. The company estimates that the 8.0 tonnes/ha numerical increase in special-grade yield could equate illustratively to about R$22,400 (≈US$4,400) in incremental gross crop value per hectare.